Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auranofin and Sirolimus in Advanced Lung Cancer
NCT01737502Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- May 2014
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of auranofin in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), sponsored by Mayo Clinic. Primary endpoints: Number of Phase 1 Patients Experiencing a Dose Limiting Toxicity at 28 days, Number of Phase 1 Patients Experiencing a Grade 3+ Adverse Event up to 5 years and 1 more. Started May 2014; status: completed.
02
Drugs
auranofin
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01737502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01737502.